Ocrelizumab was being reviewed by NICE as the first licensed treatment for Primary Progressive MS. NICE aren’t recommending it because the price tag will be different for the NHS for primary progressive MS, than the current price for treating Relapsing Remitting MS. Prof G explains how the same treatment can have two different price tags.
If you think it’s unfair that NICE aren’t recommending the first licensed drug for primary progressive MS, Gavin recommends writing to your MP. We’ve put together a template letter to download on this link. https://goo.gl/K2kxg3
MS Reporter: Rachel
Expert: Gavin Giovannoni, Consultant Neurologist, BARTS, London
Professor Gavin Giovannoni has an MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath amongst his qualifications. He is the Chair of Neurology at Barts and The London School of Medicine. His research interests have focused around multiple sclerosis and inflammatory disorders of the central nervous system. His teaching focuses on clinical neurology and neuroimmunology.